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Despite therapeutic advances, glioblastoma multiforme (GBM) remains a lethal disease.
The inﬁltrative nature of this disease and the presence of a cellular population
resistant to current medical treatments account for the poor prognosis of these patients.
Growing evidence indicates the existence of a fraction of cancer cells sharing the functional
properties of adult stem cells, including self-renewal and a greater ability to escape
chemo-radiotherapy-induced death stimuli. Therefore, these cells are commonly deﬁned
as cancer stem cells (GBM-SCs). The initial GBM-SC concept has been challenged,
and reﬁned according to the emerging molecular taxonomy of GBM. This allowed to
postulate the existence of multiple CSC types, each one driving a given molecular entity.
Furthermore, it is becoming increasingly clear that GBM-SCs thrive through a dynamic
and bidirectional interaction with the surrounding microenvironment. In this article, we
discuss recent advances in GBM-SC biology, mechanisms through which these cells adapt
to hostile conditions, pharmacological strategies for selectively killing GBM-SCs, and how
novel CSC-associated endpoints have been investigated in the clinical setting.
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INTRODUCTION
Glioblastoma multiforme (GBM, World Health Organization
grade IV gliomas) is the most common and lethal form of primary
brain tumors. Despite multimodality management, consisting in
surgery followed by adjuvant chemo-radiotherapy with temozolo-
mide, GBM remains a devastating disease with a 2-year survival
rate in the range of 10–25% (Stupp et al., 2005). Although the
use of molecular targeted agents in deﬁned genetic backgrounds
is changing the treatment of many solid tumors, GBM contin-
ues to be an orphan disease. The impact on the overall survival
(OS) rate achievedwith the anti-vascular endothelial growth factor
(VEGF) monoclonal antibody bevacizumab, the only molecular
targeted agent currently approved by the FDA, has not yet been
understood (reviewed in Patel et al., 2012). Furthermore, many
small molecule inhibitors stopped the clinical developmental path
prematurely, despite an apparently solid biological background
underlying their evaluation in GBM, whereas immunotherapies
and toxin-ligand conjugates, which have shown promise in early
clinical trials, require larger randomized studies. Apart from these
disappointing results, major breakthroughs in recent years have
signiﬁcantly contributed in deciphering the biology of GBM.
Firstly, themolecular taxonomyof thedisease is rapidly expanding.
The Cancer Genome Atlas Network recently cataloged genomic
defects of GBM. These efforts allowed to classify GBM into dis-
tinct molecular entities, each one characterized by a speciﬁc gene
expression proﬁle and a different set of mutant genes (Verhaak
et al., 2010). The identiﬁcation of proneural, neural, classical,
and mesenchymal subtypes suggested that each subtype should
be approached as a distinct disease, given the potential diversity
in the disease’s course and, even more importantly, in its sensi-
tivity to pathway-focused inhibitors. As a result, novel molecular
classiﬁers are expected to turn GBM into multiple rare diseases,
thus revolutionizing the current clinical trial methodology that
will require novel endpoints and enrichment strategies. Secondly,
our knowledge on the biological mechanisms underlying tumor
formation and evolution have been implemented with the discov-
ery of a cellular hierarchy within the tumor, which makes only a
fraction of cancer cells worth targeting. The cellular pool responsi-
ble for tumor propagation possesses stem-like traits, consequently
these cells have been deﬁned as cancer stem cells (CSCs). CSCs
have been successfully isolated in most hematological malignan-
cies and solid tumors, including GBM (Bonnet and Dick, 1997;
Al-Hajj et al., 2003; Singh et al., 2003; Ricci-Vitiani et al., 2007;
Eramo et al., 2008; Todaro et al., 2010). In this article, we discuss
the origin and evolution of the CSC concept applied to primary
brain tumors, pharmacological strategies endowed with potential
anti-CSC properties, and how the CSC concept has been applied
to the clinic.
THE EVOLUTION OF THE CANCER STEM CELL MODEL
The heterogenic nature of tumors is evident in the clinical set-
ting, where different lesions present different, or even opposite,
patterns of response following systemic anticancer therapy. This
has been recently documented at the molecular level. Different
metastatic sites possess, other than a common panel of mutations,
also “private” alterations that make them unique (Gerlinger et al.,
2012). Tumor heterogeneity has emerged since the earliest patho-
logical examinations, and originally explained in 1858 by Rudolf
Virchow who proposed that tumors arise from embryo-like cells
(Virchow, 1855). This theory was further reﬁned by Cohnheim
and Durante with the “embryonal rest theory” (Durante, 1874;
Cohnheim, 1875). According to this model, embryonic remnants
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are present throughout the body, usually lying in a dormant state
but, when reactivated, they give rise to tumors. The heterogenic
nature of cancer and the dynamics existing within a tumor cell
population have been connected to evolutionary principles and
shaped upon Darwinian laws. Each clone has the same ability
to proliferate and to retain tumorigenicity. However, the ran-
dom occurrence of mutations leads to the emersion of dominant
clones that acquire a survival advantage over other cells, having
a greater ability to thrive in a hostile microenvironment and to
adapt to microenvironmental perturbations, ultimately prevailing
over cells that do not acquire these advantageous traits (“stochastic
clonal evolution model”). In recent years, a novel and seemingly
contradictory model was proposed following the identiﬁcation
and characterization of a rare fraction of tumorigenic cancer cells
resembling normal stem cells, thanks to their ability to self-renew
and to differentiate into different lineages. The CSC model pos-
tulated the existence of a rigid and immutable hierarchy within
a tumor (“hierarchical model”), which is organized in a pyrami-
dal manner with few CSCs at the apex representing the founders
of the entire population. However, the antithetic nature of the
“clonal evolution” and “hierarchical” models was later excluded
with an in-depth characterization of embryonic, adult, and CSCs.
The fact that the “stemness” state can be induced in differentiated
cells was originally demonstrated with the forced expression of
four embryonic stem cell-speciﬁc transcription factors in ﬁbrob-
lasts (Takahashi and Yamanaka, 2006). Subsequently, also the CSC
state appeared to ﬂuctuate, and be affected by multiple conditions
including hypoxia, low pH, exposure to paracrine-acting signals
such as stimulation with hepatocyte growth factor, and activation
of the epithelial-mesenchymal transition (EMT) program (Mani
et al., 2008; Li et al., 2009; Vermeulen et al., 2010; Hjelmeland
et al., 2011). Under these conditions, differentiated cancer cells
acquire the operative criteria of CSCs, including the expression of
stem cellmarkers and clonogenic ability determinedwith limiting-
dilution assay. It is therefore foreseeable that exogenous inﬂuences
are involved in the process of maintaining and enriching CSCs,
highlighting the fact that the retention/acquisition of stem-like
features is a dynamic process. Furthermore, microenvironmental
inﬂuences, which represent a mainstay of evolutionary principles,
also affect the biology of CSCs. Also the original rigidity of the
CSC model that stated that only stem-like cells can propagate
the tumor was reviewed. Not only CSCs, but also their proxi-
mal progeny, can propagate the tumor although with a different
temporal pattern (Dieter et al., 2011). Finally, the genetic het-
erogeneity of cancer propagating cells suggests a clonal evolution
within the stem cell pool (Anderson et al., 2011). Overall, evidence
mentioned above allowed to envision a combined clonal-stem cell
model (Figure 1). The ﬁrst hint supporting the existence of CSCs
in GBM was provided in 2003 and 2004 (Singh et al., 2003, 2004),
and conﬁrmed by independent research groups (Galli et al., 2004).
These studies revealed the existence of a rare fraction of cancer
cells able to self-renew, as measured by neurosphere-formation
assay and tumor propagation in vivo in intracranial limiting dilu-
tion assays. The ﬁrst wave of investigation conducted with GBM
stem cells (GBM-SCs) suggested that only the CD133+ population
was endowed with clonogenic ability and was able to recapitulate
the parental disease after inoculation in immunocompromised
FIGURE 1 |Theories proposed for explaining the origin and evolution
of cancer. (A) Different mutant clones cohabit the tumor, each one with the
same ability to proliferate and to retain tumorigenicity, and the random
occurrence of genetic events confers dominant traits to some of them, (B)
the CSC model originally postulated that a stem-like cell located at the apex
of the tumor pyramid is the precursor of the whole tumor population, and
(C) the combined clonal-stem cell model suggests that CSCs can undergo
clonal evolution, and therefore multiple CSC clones coexist within the
tumor.
mice. However, subsequent studies revealed that the stem-like
state is not restricted to CD133+ cells, but also CD133− cells can
fulﬁll criteria to be deﬁned as CSCs (Beier et al., 2007; Piccirillo
et al., 2009), a ﬁnding that is consistent with studies performed
with other CSC types (Shmelkov et al., 2008). These observations
suggested that CD133 cannot be deﬁned as a universal marker
for GBM-SCs, and raised the hypothesis that it might serve for
deﬁning a subgroup of brain tumor stem cells, potentially identi-
fying a given molecular entity. Furthermore, the presence of both
CD133+ and CD133− self-renewing tumor-initiating cells within
a tumor indicates the coexistence of multiple CSC clones, a ﬁnding
substantiated by differences in gene expression and growth kinet-
ics of orthotopic grafts between CD133+ and CD133− cells (Chen
et al., 2010). The cytoarchitecture of GBM, consisting in normoxic
cells in the periphery, hypoxic cells in the center and necrotic
cells in the inner core, further suggested that different microen-
vironmental conditions might affect CSC properties. Consistent
with this, cells residing in the inner core and in the intermedi-
ate layer display a more immature phenotype, and possess greater
clonogenic ability compared with more peripheral cells (Pistol-
lato et al., 2010). However, the interaction of GBM-SCs with the
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surrounding non-cancerous tissue is bidirectional. If, on the one
hand, microenvironment factors inﬂuence the biological behav-
ior of GBM-SCs, on the other hand these cells demonstrated the
ability to recreate more favorable conditions, as demonstrated by
their ability to actively participate in the generation of new blood
vessels through producing angiocytokines, and their direct differ-
entiation into endothelial-like cells (Bao et al., 2006a; Ricci-Vitiani
et al., 2010; Wang et al., 2010). Overall, the diversity existing in
the CSC pool highlights the increasing complexity of the CSC
paradigm in GBM, and the importance of gaining a deeper under-
standing of the evolutionary dynamics at the apex of the tumor
pyramid.
CONTROVERSIES IN GLIOBLASTOMA MULTIFORME STEM
CELLS
The “stem cell-centric” model of cancer originally envisioned
an adult stem cell as the target of oncogenic hits. Accordingly,
the malignant transformation of these cells gives rise to cancer
cells that maintain stem-like traits. This has fostered the trans-
lation of knowledge about stem cell biology to the pathobiology
of cancer, allowing the identiﬁcation of CSC-restricted pathways
valuable for pharmacological inhibition, and to deﬁne a fraction
of cancer cells with increased resistance to chemo-radiotherapy
compared to the bulk of tumor cell mass. Nevertheless, there
are much controversies over the existence, origin, and nomen-
clature of CSCs (Lathia et al., 2011; Valent et al., 2012). The link
existing between adult stem cells and CSCs has been the focus
of many investigations. Although genetically engineered mouse
models provided hints that GBM originates from the malignant
transformation of neural stem/progenitor cells (reviewed in Lathia
et al., 2011), these results should be interpreted with caution. For
instance, current animal models did not exclude the possibility
that also non-stem cells can give rise to GBM, when manipu-
lated with multiple and sequential mutational hits. Consistent
with this, recent studies demonstrating that GBM can be gen-
erated by cells that do not reside within neurogenic niches (Zhu
et al., 2009). Functionally, CSCs are deﬁned as a subpopulation
of tumor-initiating cells having the ability to reconstitute the cel-
lular heterogeneity typical of the original tumor. Operatively, to
deﬁne CSCs some criteria need to be fulﬁlled, such as expres-
sion of a repertoire of markers common to stem and progenitor
cells, ability to self-renew, and capability to reproduce the parental
tumor upon injection into immunocompromised mice. Although
informative, the expression of a single marker cannot be consid-
ered as a general principle for deﬁning CSCs, nor a somatic stem
cell. As discussed above, CD133 expression was originally used
for GBM-SCs characterization. Nevertheless, this criterion nowa-
days appears to be oversimpliﬁed, while the validation of novel
markers and their combined use might add a further level of reli-
ability to current isolation protocols. The ability to self-renew and
to differentiate into multiple lineages is a hallmark of stem cells,
enabling them tomaintain tissue homeostasis and to replace senes-
cent or dying cells. Self-renewal of adult stem cells is determined
through sphere-forming ability under non-adherent culture con-
ditions. Given the analogies supposed to exist between adult stem
cells and CSCs, the same assay is used for deﬁning putative CSCs.
Even though spheroids are enriched for CSCs, one should consider
that tumorsphere-formation assay does not provide an exact, nor
an exclusive, measurement of self-renewal ability, since this assay
evaluates further biological properties, such as adhesion indepen-
dence, survival, and proliferation. Overall, the ability to recreate
the original tumor upon the delivery into the murine background
represents the most critical factor in deﬁning CSCs. Furthermore,
our unpublished data suggests that CSCs generates tumors main-
taining the original molecular portrait of the parental neoplasia,
as demonstrated by mapping pathway activation through reverse-
phase phosphoprotein microarray. Finally, microarray analyses
demonstrated the intrinsic heterogeneous nature of GBM. This
suggests that each molecular entity might stem from a differ-
ent cell of origin (Phillips et al., 2006; Verhaak et al., 2010).
Overall, further preclinical investigations are needed for resolv-
ing controversies surrounding the CSC model in GBM, and for
acquiring a deeper understanding of subtype-restricted molecular
signals.
BRAIN TUMOR STEM CELLS AND RESISTANCE TO CURRENT
ANTICANCER THERAPIES
Growing evidence indicates that CSCs are less vulnerable to
chemo- and radiotherapy than the bulk of tumor cells (reviewed
in Maugeri-Saccà et al., 2011a). Among multiple mechanisms that
defend CSCs against harmful insults, is the capacity to rapidly
correct genetic lesions generated by DNA damaging agents, such
as ionizing radiation and alkylating agents (reviewed in Maugeri-
Saccà et al., 2012). Radioresistance of GBM-SCs was originally
connected with enhanced DNA repair ability. GBM-SCs showed a
more effective activation of DNA damage checkpoints compared
with tumor cells without stem cell properties, a phenomenon
reverted with the abrogation of the cell cycle checkpoint con-
trollers Chk1 and Chk2 (Bao et al., 2006b). However, this ﬁnding
was later questioned. Although enhanced activation of Chk1 and
Chk2 was found in untreated CD133+ compared to CD133−,
the stem cell fraction did not display increased DNA repair
proﬁciency (Ropolo et al., 2009). Evidence that the population
doubling time was signiﬁcantly increased in GBM-SCs compared
to non-stem cells suggested that their radioresistance is due to
an elongated cell cycle, resulting from enhanced basal activa-
tion of checkpoint proteins. The biological relevance of the DNA
damage machinery was further extended by proving that the self-
renewal-linked protein Bmi1 mediates radioresistance through
the recruitment of multiple DNA damage repair components
(Facchino et al., 2010). Consistently, Bmi1 deﬁciency increased
sensitivity to radiation consequently to impaired DNA double-
strand break response. This picture was further complicated by
comparing radioresistance between GBM-SCs and established cell
lines. Although within a subset of CSCs the CD133+ pool was
more resistant to ionizing radiation as compared to CD133−,
CSCs displayed impaired DNA repair and were more sensitive
to irradiation than commercial cell lines (McCord et al., 2009).
Beyond DNA repair capacity, additional mechanisms have been
associated with radioresistance. Irradiation of glioma cells induces
autophagy to a wider extent in the CD133+ compartment, which
expresses higher levels of autophagy-related proteins (Lomonaco
et al., 2009). Induction of autophagy conferred radioresistance to
these cells, a property abolished with autophagy inhibitors that
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decreased survival and neurosphere-forming ability. The acti-
vation of self-renewal pathways, such as Notch and Wnt, has
been associated with radioresistance (Wang et al., 2010; Kim et al.,
2012). Notably, gamma-secretase and Wnt inhibitors sensitized
GBM-SCs to radiation, decreasing clonogenic ability and impair-
ing xenograft formation. Also extrinsic mechanisms play a role in
the ability of GBM-SCs to survive ionizing radiation. Cells irradi-
ated in vivo accumulate less genetic damages and express higher
levels of genes related to reactive oxygen species metabolism as
compared to in vitro irradiated cells (Jamal et al., 2010). This
indicates that microenvironmental cues may affect the suscepti-
bility to ionizing radiation by improving DNA repair capacity.
The notion that current medical treatments preferentially kill
non-CSCs allowed to postulate an enrichment of the stem cell
compartment following exposure to radio- and chemotherapy.
Even though explored in a small study cohort, accumulation of
CD133+ cells was documented after stereotactic radiosurgery and
external beam radiation therapy, thus suggesting that glioma stem-
like cells can survive high-dose irradiation (Tamura et al., 2010).
While radioresistance of GBM-SCs is widely accepted, the ques-
tion whether or not CSCs account for the limited efﬁcacy of
chemotherapy in GBM still remains controversial. Despite ﬁnd-
ings from studies investigating the sensitivity of GBM-SCs to
chemotherapy result inconclusive, with some reports describing
an increased resistance (Eramoet al., 2006) andothers an increased
susceptibility (Beier et al., 2008), all studies reported an over-
all increased resistance to temozolomide of MGMT-expressing
GBM-SCs (reviewed in Beier et al., 2011). Furthermore, temozolo-
mide resistance has been associated with the intratumoral hypoxic
gradient. While CSCs residing in the periphery showed suscepti-
bility to temozolomide, CD133+ cells located in the inner core
were resistant and displayed the highest expression of MGMT
(Pistollato et al., 2010). More recently, investigators identiﬁed a
restricted cell population capable to repopulate the tumor follow-
ing chemotherapy using a genetically engineered mouse model
of glioma, thus providing novel hints on the contribution of
CSCs on tumor recurrence despite adjuvant therapy (Chen et al.,
2012). Pharmacological abrogation of stem cell-restricted path-
ways seems to enhance the efﬁcacy of standard chemotherapeutics.
Inhibition of either Hedgehog or Notch pathway modulates the
effects of temozolomide in CSCs potentiating its antitumor activ-
ity, thus setting the biological basis for testing these combinations
in clinical trials (Gilbert et al., 2010; Ferruzzi et al., 2012). Addi-
tional molecular mechanisms have been associated with the ability
of CSCs to survive standard chemotherapeutic agents. Among
these are the increased function of ATP-binding cassette trans-
porters, a system committed to actively transporting chemicals
out of the cells, and a tendency toward an anti-apoptotic state
(reviewed in Maugeri-Saccà et al., 2011b). Also, microenviron-
mental stimuli contribute to chemo-radioresistance. The EMT
is an evolutionarily conserved process that is essential for tissue
remodeling during morphogenesis (Lim and Thiery, 2012). The
activation of EMT-associated transcription factors leads to a dras-
tic cytoskeletal rearrangement, through which epithelial cells lose
their polarized organization and cell–cell junctions. Therefore,
cells undergoing EMT acquire a high motile, mesenchymal-like
phenotype. Several lines of evidence connected EMT with cancer
invasion, metastasis, ability to evade the host immune response
to the tumor, resistance to current cancer therapeutics and CSC
generation (reviewed in Tiwari et al., 2012). While EMT induc-
tion has been prominently associated with the paracrine-acting
transforming growth factor β (TGF-β) pathway (Tiwari et al.,
2012), a wave of preclinical investigations revealed that a sim-
ilar outcome is elicited by the self-renewal-associated pathways
Sonic Hedgehog (Shh), Notch, and Wnt (Ohta et al., 2009; Wang
et al., 2009; Gupta et al., 2010). Recently, in squamous cell carci-
noma investigators revealed the coexistence of CSCs with either
epithelial or mesenchymal traits, and endowed with distinct bio-
logical properties (Biddle et al., 2011). This ﬁndingwas in linewith
the “migrating cancer stem cell” concept (Brabletz et al., 2005 ),
according to which the transient expression of EMT-related genes
enable CSCs to migrate to a distant site, where the opposite path
takes place (mesenchymal-epithelial transition). This epithelial re-
differentiation leads to tumor growth in a foreign soil, and to the
generation of lesions with the same epithelial characteristics as the
original tumor. Although intriguing, it is worth considering that
controversies exists around the role of EMT (reviewed in Bastid,
2012). These fundamentally stem from the difﬁculty of providing
direct evidence of EMT in human tumor specimens, which can-
not be fully explained by the presence of sarcomatoid elements in
epithelial cancers.
TARGETING GLIOBLASTOMA MULTIFORME STEM CELLS
Reﬁning protocols for CSCs isolation and expansion has enabled
investigators to identify CSC-restricted molecular networks
valuable for pharmacological abrogation. Schematically, com-
pounds with potential anti-GBM-SCs activity can be classiﬁed
as molecules targeting canonical and self-renewal pathways,
agents inducing differentiation, and molecules depriving CSCs
of microenvironmental stimuli.
TARGETING CANONICAL PATHWAYS
The epidermal growth factor receptor (EGFR) signaling is one of
the most common deregulated pathways in cancer. The mutant
and constitutively active variant EGFRvIII, which is found in
25% of GBM and leads to increased Akt signaling (Choe et al.,
2003), has been linked to GBM-SCs function. EGFRvIII seems
to control GBM-SCs fate at multiple levels and through different
molecular mechanisms. The EGFR-Akt-Smad5 axis induces the
inhibitor of differentiation 3 (Id3) that, in turn, promotes neu-
rosphere formation (Jin et al., 2011). Furthermore, a telomerase
activity-deﬁcient form of telomerase reverse transcriptase (TERT)
was shown to induce EGFR expression in glioma cells, in a pro-
cess coupled with the acquisition of stem-like traits (Beck et al.,
2011). Consistent with the biological relevance of aberrant EGFR
activation in glioma, GBM-SCs have been reported to be more
dependent on Akt signaling than the non-CSC counterpart. This
was demonstrated by the ability of pharmacological Akt inhibitors
to disrupt neurosphere generation and delay intracranial tumor
formation (Eyler et al., 2008). Even though acting downstream
the pathway has been proposed as an effective way for GBM-
SCs targeting (Bleau et al., 2009), it is worth considering that the
phosphoinositide 3-kinase (PI3K)/AKT pathway inhibitor enzas-
taurin failed to demonstrate superiority over lomustine in a phase
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III trial conducted in patients with recurrent GBM (Wick et al.,
2010). Moreover, further reports shed doubt on the therapeutic
relevance of EGFR inhibition as anti-CSC strategies. For instance,
EGFR abrogation failed to prevent tumorigenesis of transformed
neural stem cells or GBM-SCs in vivo (Hide et al., 2011) and, more
recently, EGFR inhibition in the mutant background paradoxi-
cally increasedGBM-SCsmalignancy (Jin et al., 2012). In addition,
invasiveness of GBM-SCs did not correlate with PI3K-Akt path-
way activation (Wakimoto et al., 2012). Recently, a compensatory
activation of others ERBB family receptors was observed in GBM-
SCs following EGFR abrogation, thus raising the possibility that
efﬁcient anti-EGFR therapy requires the co-targeting of multiple
family members (Clark et al., 2012). To sum up, a deeper under-
standing of EGFR biology in CSCs, which considers the molecular
taxonomy of the disease, is required for improving the anti-CSC
properties of these agents. The TGF-β pathway is involved in mul-
tiple biological activities spanning from immunosuppression to
migration and invasion of cancer cells. The ability of TGF-β and
leukemia inhibitory factor (LIF) in preventing differentiation and
in inducing self-renewal of GBM-SCs, but not of normal human
neuroprogenitors, has been recently demonstrated via a molecular
cascade requiring the activationof the JAK-STAT-pathway (Peñue-
las et al., 2009). Consistently, the pro-CSC effects of the pathway
were neutralized throughTGF-β receptor I inhibition (Anido et al.,
2010). Furthermore, a TGF-β-Sox4-Sox2 pathway was described
to be essential in retaining the stemness state (Ikushima et al.,
2009). In more detail, the stem cell marker Sox2 is induced by
TGF-β via Sox4 activation, while pathway inhibition promotes
differentiation, impairs tumorigenicity, and extends the survival
of mice bearing CSC-generated orthotopic glioma. Interestingly,
differences in the transcriptional activity of the TGF-β/bone mor-
phogenetic protein signaling seem to identify distinct CSCs that
give rise to different molecular subtypes of GBM (Lottaz et al.,
2010). As mentioned above, STAT3 was identiﬁed as a regulator
of self-renewal in GBM-SCs. STAT3 is a transcriptional regula-
tor involved in a wide range of cellular activities such as immune
response, stemcellmaintenance, and tumorigenesis, and its associ-
ation with gliomagenesis has become increasingly evident. STAT3
inhibition impairs GBM-SCs proliferation and disrupts stem cell
maintenance (Sherry et al., 2009). Furthermore, the constitutively
active STAT3 pathway in GBM-SCs contributes to the inhibition
of T cell proliferation and activation, while this immunosuppres-
sive status was diminished with STAT3 blockade (Wei et al., 2010).
The list of potential pathway-focused inhibitors targeting deregu-
lated canonical signals in GBM-SCs includes also MET inhibitors.
The MET tyrosine kinase receptor is an established oncogenic sig-
nal known to stimulate survival, proliferation, and invasion of
GBM cells. High levels of MET were found in GBM specimens
topographically localized in perivascular regions. This fraction
of MET-expressing cells was endowed with high clonogenic and
tumorigenic ability, and displayed resistance to radiation, while
MET inhibition hampered their growth and invasiveness both in
vitro and in vivo (Joo et al., 2012). c-MET activation was also
able to counteract the effects of forced differentiation (Li et al.,
2011). Notably,MET expression was associated with neurospheres
expressing the gene signature of mesenchymal and proneural sub-
types, while it was absent in neurospheres expressing the classical
subtype signature, being therefore mutually exclusive with EGFR
abnormalities (De Bacco et al., 2012).
TARGETING SELF-RENEWAL PATHWAYS
One of the assumption of the CSC model is that these cells share
many functional properties with their normal counterpart. The
Notch and Hedgehog pathways are essential for maintaining sev-
eral types of adult stem cells, including neural stem cells (reviewed
in Lathia et al., 2008; and in Ruiz iAltaba et al., 2007). Aberrant
Notch signaling is common in tumors, and deregulated Notch
activity has been linked to GBM-SCs. Notch inhibition achieved
with gamma-secretase inhibitors (GSIs) hampered the formation
of neurospheres in vitro and tumorigenicity in vivo (Fan et al.,
2010). The depletion of CD133+ was accompanied by the reduc-
tion of putative CSC markers, and connected with decreased
phosphorylation of AKT and STAT3. GBM-SCs are thought to
reside within dedicated microarchitectonic entities that provide
structural and functional support, commonly deﬁned as vascular
niches (Calabrese et al., 2007). By taking advantage of a three-
dimensional model that preserves the cytoarchitecture of glioma
and a functional stromal compartment, investigators revealed
that endothelial cells modulate the self-renewal of GBM-SCs in
a process disrupted by Notch inhibition (Hovinga et al., 2010).
How Notch links angiogenesis and self-renewal is mechanistically
explained by co-culturing Notch ligand-expressing human brain
microvascular endothelial cells with neurospheres. Under these
conditions endothelial cells promote growth and self-renewal of
GBM-SCs, while the knockdown of Notch ligands abrogates this
process (Zhu et al., 2011). Even though blocking Notch signaling
with GSIs appears to be a valuable strategy, from which promising
results have emerged from early clinical trials, it is worth consid-
ering that different Notch paralogs are known to possess different,
or even opposite, biological functions. Since this notion poten-
tially translates into either unnecessary side effects or reduced
antitumor activity, more focused strategies for pathway inhibi-
tion have been explored. Nevertheless, the therapeutic potential
of anti-Delta-like 4 therapies was counterbalanced by severe tox-
icity consisting in liver alterations and vascular neoplasms (Li
et al., 2010; Yan et al., 2010). The Shh is a key regulatory pathway
during embryogenesis. Recently, the ﬁrst-in-class Smoothened
inhibitorVismodegib (GDC-0449) has been approved for treating
basal-cell carcinoma, and displayed encouraging activity against
medulloblastoma (Rudin et al., 2009; Von Hoff et al., 2009). The
pathway is deregulated in multiple tumor types, and its aber-
rant activation sustains self-renewal and tumorigenic potential
of GBM-SCs (Clement et al., 2007). Furthermore, antagoniza-
tion of Shh pathway synergizes with temozolomide, leading to
a more pronounced inhibition of GBM-SCs proliferation. A selec-
tive depletion of GBM-SCs was achieved with cyclopamine, as
it has been further conﬁrmed by reduced aldehyde dehydroge-
nase activity and Hoechst dye excretion (Bar et al., 2007). More
importantly, viable cells injected intracranially following Shh
inhibition failed to form a tumor, thus indicating an efﬁcient tar-
geting of tumor-propagating cells. In addition, the association
of cyclopamine with the EGFR tyrosine kinase inhibitor erlotinib
demonstrated synergistic activity against GBM-SCs (Eimer et al.,
2012). Overall, these studies indicate that Shh pathway is crucial
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for regulating GBM-SCs fate, and that its abrogation may selec-
tively target GBM-SCs, or render them more sensitive to current
therapies.
DIFFERENTIATION-INDUCING AGENTS
Induction of differentiation with retinoic acid is a therapeutic
approach commonly used for treating hematological malignan-
cies that has been also proposed in solid tumors. When exposed
to retinoic acid GBM-SCs underwent both growth arrest and
expression of lineage-speciﬁc differentiation markers, in a process
associated with the down-regulation of Notch-related genes (Ying
et al., 2011). The differentiation induced by retinoic acid produced
chemosensitizing and radiosensitizing effects, and decreased the
secretion of the angiocytokines VEGF and basic ﬁbroblast growth
factor (Campos et al., 2010). Apart from retinoic acid, the grow-
ing body of knowledge on the differentiation path of adult stem
cells is fuelling alternative ways for forcing CSCs to differentiate.
Bone morphogenetic proteins (BMPs), members of the TGF-β
superfamily, instruct cell fate during neural development by inter-
acting with their cognate receptors (BMPR), ultimately triggering
the Smad signaling cascade. Based on this background, it has been
demonstrated that BMP4 induces differentiation of GBM-SCs and
inhibits tumor growth in vitro through the activation of the canon-
ical signaling, a ﬁnding conﬁrmed in vivo (Piccirillo et al., 2006).
The connection between BMPs and stem cell differentiation has
been further enforced by demonstrating that GBM-SCs can epi-
genetically regulate BMPRs, a process that produces a shift toward
a fetal phenotype overcoming the pro-differentiation effects of
BMPs. Consistently, the forced expression of BMPR1B restored the
pro-differentiative effects of the pathway and impaired tumori-
genicity (Lee et al., 2008). Recently, novel mechanistic insights
on the role of BMP pathway have been provided. BMP2 was
found to be able to sensitize GBM-SCs to temozolomide by induc-
ing down-regulation of hypoxia-inducible factor-1α and MGMT
(Persano et al., 2012). Investigators revealed that a BMP7 vari-
ant decreasedGBM-SCs proliferation, endothelial cord formation,
and stem cell marker expression in vitro, and reduced brain inva-
sion, angiogenesis, and mortality in an orthotopic mouse model
(Tate et al., 2012). Interferon-beta (IFN-β) has been proposed as a
further differentiation-inducing agent. IFN-β-mediated differen-
tiation led to reduced proliferation and self-renewal, producing
chemosensitizing effects (Yuki et al., 2009). Finally, stem cell
transcription factors including Sox2,Oct4, andNanog are involved
in the maintenance and functions of embryonic and adult stem
cells (Cheng et al., 2010), and are critical for cell reprogramming
and generation of inducible pluripotent stem cells (Takahashi and
Yamanaka, 2006). Even though targeting these molecular effec-
tors induces differentiation of GBM-SCs, it is still controversial
whether or not these strategies can be translated to the clini-
cal setting, being potentially burdened by “off-target” effects on
tissue-resident stem cells.
TARGETING THE HYPOXIA RESPONSE
Hypoxia is a hallmark of GBM. Low oxygen conditions are sensed
by hypoxia inducible factors (HIFs), which mediate an adaptive
response consisting in the production of angiogenic cytokines
that stimulate the generation of new blood vessels. Newly formed
vessels are, however, disorganized and dysfunctional, thus fuelling
a vicious circle between hypoxia and neoangiogenesis. As dis-
cussed above, GBM-SCs directly participate in this aberrant loop
through different biological mechanisms. It is known that there is
a close connection between oxygen levels and stem cells (Cheng
et al., 2010). Hypoxic niches are involved in maintaining normal
stem cells, as demonstrated in the hematopoietic system. Further-
more, hypoxia prevents the differentiation of neural stem cells,
promotes the self-renewal of embryonic stem cells, and enhances
the generation of induced pluripotent stem cells. Similarly, it
has been suggested that hypoxic niches are the environment in
which CSCs thrive, while disrupting these privileged microenvi-
ronments may provide a new approach for targeting GBM-SCs.
Functional studies through RNA interference revealed that both
HIF1α and HIF2α are required for GBM-SCs (Li et al., 2009),
and that hypoxia drives the expansion of GBM-SCs (Soeda et al.,
2009). Interestingly, hypoxia differentially induces HIF members
in stem versus non-stem GBM cells. While HIF1α is induced in
both GBM-SCs and non-stem cells, HIF2α and its target genes are
speciﬁcally up-regulated in GBM-SCs. Furthermore, HIF2α was
not expressed in normal neural progenitors, thus suggesting that
HIF2α inhibition might spare normal stem cells. Recently, it has
been demonstrated that the autocrine axisVEGF-VEGF receptor 2
(VEGFR2)-neuropilin-1 drives GBM-SCs growth (Hamerlik et al.,
2012). Authors found that the limited efﬁcacy of bevacizumab was
correlatedwith this type of autocrine signaling, which is associated
with receptor recycling and the existence of a cytosolic pool of
activeVEGFR2. Conversely, GBM-SCs viability was affected by the
inhibition of the VEGFR2 tyrosine kinase activity. Overall, studies
mentioned above suggest that targeting hypoxia/neoangiogenesis
may provide novel strategies for GBM-SCs targeting. Neverthe-
less, the study of the CSC-microenvironment interactions is only
at the beginning, and a more in-depth characterization is required
for improving the therapeutic potential of these compounds in the
clinical scenario. Table 1 summarizes pharmacological strategies
investigated for targeting GBM-SCs
GLIOBLASTOMA STEM CELLS IN THE CLINICAL SETTING
The discovery of CSCs added a further level of complexity to
the biology of tumors. In the past decade, efforts in dissecting
their functional properties allowed the ﬁrst wave of transla-
tional investigations. Aims of these studies were to explore the
correlation existing between CSC-related parameters and clin-
ical outcomes. Different predictors were investigated, such as
expression of putative stem cell markers (Pallini et al., 2008),
sphere-forming efﬁciency (Laks et al., 2009), stem cell-related sig-
natures (Liu et al., 2007), and polymorphisms in stem cell genes
(Gerger et al., 2011). By evaluating CD133 expression by immuno-
histochemistry in a series of 95 gliomas of various grade and
histology, authors reported an inverse correlation between the
proportion of CD133+ cells, and their topological organization
in clusters, and progression-free survival (PFS) and OS (Zep-
pernick et al., 2008). In this study, the association of CD133
expression and shorter PFS and OS occurred independently from
established clinical and pathological prognostic factors such as
tumor grade, extent of resection, and patient age. This ﬁnding
was later conﬁrmed in an independent study. The in vitro
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Table 1 | Pharmacological strategies for targeting GBM-SCs.
Strategy Targets Reference
Canonical pathway inhibitors EGFR, TGF-β, c-MET, PI3K/Akt, STAT3 Eyler et al. (2008), Bleau et al. (2009), Sherry et al. (2009),
Anido et al. (2010), Jin et al. (2011), Joo et al. (2012)
Self-renewal pathway inhibitors Sonic Hedgehog, Notch Bar et al. (2007), Fan et al. (2010)
Differentiation-inducing agents Retinoic acid, BMPs, IFN-β Piccirillo et al. (2006), Yuki et al. (2009), Ying et al. (2011),
Tate et al. (2012)
CSC-microenvironment disrupting agents HIFs, VEGF/VEGFR axis, Notch Li et al. (2009), Zhu et al. (2011), Hamerlik et al. (2012)
DNA damage response Chk1 and Chk2 Bao et al. (2006b), Ropolo et al. (2009)
generation of CSCs and the expression of CD133 correlated with
long-term outcomes, while the co-expression of CD133 and Ki67
identiﬁed a fraction of patients with very short PFS and OS
(Pallini et al., 2008). The prognostic value of neurosphere for-
mation and tumorigenic capacity was further conﬁrmed in an
analysis of 32 GBM patients (Laks et al., 2009). Notably, in mul-
tivariate analysis neurosphere generation remained a signiﬁcant
predictor of poor clinical outcomes. Increased CD133 expression
was detected in recurrent GBM (Pallini et al., 2011). Surprisingly,
CD133 expressionwas signiﬁcantly associatedwith longer survival
after tumor recurrence given that non-tumor neural stem cells
represented 20–60% of CD133+ cells in this setting. Therefore,
authors concluded that the recruitment of neural stem/progenitor
cells from surrounding brain may exert anti-tumorigenic effects.
As mentioned above, many attempts have been made for identi-
fying stem cell-associated gene expression proﬁles that correlate
with clinical parameters. By proﬁling 80 GBM, authors identiﬁed
a cluster of deregulated genes dominated by HOX components,
and therefore reminiscent of a“self-renewal” signature, which pre-
dicted poor survival and treatment resistance in patients receiving
concomitant chemo-radiotherapy (Murat et al., 2008). The HOX
signature maintained its negative prognostic value in multivariate
analysis adjusted for MGMT methylation status. An independent
HOX/stem cell gene signature was also correlated with shorter sur-
vival in pediatric high-grade glioma patients (Gaspar et al., 2010).
Although studies discussed above suggest a prognostic impact of
CSC-related endpoints, some considerations need to be taken into
account. These studies were conducted in retrospective series, and
they did not consider an independent validation set. Therefore,
prospective and adequately powered trials are required for thor-
oughly understanding the prognostic and predictive signiﬁcance
of CSC-associated parameters. Finally, the molecular taxonomy of
GBM should be taken into account when exploring the correlation
between CSCs and clinical outcomes. Several genes identifying a
given subtype are also differentially regulated between CD133+
and CD133−, thus suggesting that distinct CSCs maintain dif-
ferent molecular subtypes (Günther et al., 2008; Joo et al., 2008;
Lottaz et al., 2010).
CONCLUSION
The identiﬁcation of GBM-SCs challenged principles of experi-
mental and medical oncology, and prompted novel therapeutic
approaches. Nevertheless, most of the molecules endowed with
anti-CSC activity in the preclinical setting did not show formal
proof of effectiveness in clinical trials, highlighting the need for
a more in-depth understanding of biological principles govern-
ing CSC fate. In this scenario, disease segmentation emerging
from recent data is expected to enable more focused investiga-
tions. To this end, a thorough examination of different GBM-SC
types is required, considering that each one potentially displays a
peculiar biological behavior and a distinct spectrum of sensitivity
to pathway-focused inhibitors. Furthermore, the CSC concept is
changing. The original view that only CSCs are tumorigenic has
been questioned, as well as the existence of a rigid hierarchy. To
sum up, it is increasingly evident that a better deﬁnition of GBM-
SCs is needed, ideally within a deﬁned disease entity. Answering
these questions will help delineate the appropriate clinical con-
text for exploring effective anti-CSC therapies and CSC-related
prognostic and predictive biomarkers.
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